Chiron Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chiron

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: vinod Khurana who wrote (1)	5/17/1996 1:45:00 PM
From: vinod Khurana	of 23

Chiron Corp, Ciba Pharma, Focal Inc In Collaboration Pact SUMMIT, N.J. (Dow Jones)--Ciba-Geigy Corp.'s Ciba Pharmaceuticals unit, Chiron Corp. (CHIR) and Focal Inc. agreed to combine efforts to create treatments for restenosis. In a joint press release, the companies said the collaboration will develop new products by combining Ciba and Chiron candidate drugs with Focal's drug-delivery technology. Ciba and Chiron will receive exclusive rights in selected restenosis fields to Focal's technology. Ciba and Chiron will be responsible for developing and marketing the new products and Focal will retain manufacturing rights. Restenosis is the closing of arteries following angioplasty. Effective drug treatments may reduce the occurrence of restenosis and the resulting costs and risk. Focal's technology is to coat the interior wall of a coronary artery with a formulation of its proprietary biodegradable gel with a Ciba or Chiron drug. The drug will be slowly released as the gel degrades. V.K

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next